Skip to main content

Biotech ETFs: Orexigen Hit By Regulatory Hammer

Biotech sector and related exchange traded funds (ETFs) trade lower as one drug maker garners notoriety after regulatory hurdles puts a hold on the advancement of an anticipated diet pill. iShares Nasdaq Biotechnology (NYSEArca: IBB) is down 0.83%. First Trust Amex Biotech Index Fund (NYSEAca:...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.